Abstract

Protection of small-cell lung cancer circulating tumor cells by cellular fragmentation

Highlights

  • Small cell lung cancer (SCLC) constitutes approximately 15% of all lung cancers and is characterized by rapid metastasis, universal drug resistance upon recurrence which subsequently leads to a poor prognosis in patients[1]

  • Dissemination of SCLC appears to be correlated with a high count of circulating tumor cells (CTCs), exceeding the CTC numbers found in carcinomas of breast, colon and prostate by several magnitudes[5]

  • SCLC CTC cell lines were obtained from blood samples of patients diagnosed with EDSCLC prior to initiation of second-line chemotherapy

Read more

Summary

Introduction

Small cell lung cancer (SCLC) constitutes approximately 15% of all lung cancers and is characterized by rapid metastasis, universal drug resistance upon recurrence which subsequently leads to a poor prognosis in patients[1]. The initial choice of chemotherapy for patients with extended disease (ED)-SCLC includes using platinum-based regimens in combination with etoposide and immune checkpoint inhibitors. This yields high response rates but tumors may invariably relapse and exhibit increased chemoresistanceresulting in a 2-year survival less than 10%[2]. Dissemination of SCLC appears to be correlated with a high count of circulating tumor cells (CTCs), exceeding the CTC numbers found in carcinomas of breast, colon and prostate by several magnitudes[5]. Several studies have reported a higher metastatic potential of CTC aggregates, defined as clusters of different cells[6]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.